Market Research International

Global Kidney Cancer Drugs Market 2015-2019

Press Release   •   Aug 10, 2015 02:49 EDT

About Kidney Cancer
Kidney cancer also known as renal cancer affects the kidney cells. RCC is the most common form of kidney cancer in adults and Wilms' tumor in children. The exact cause of the disease is not yet known. The symptoms of renal cancer are often confused with other kidney disorders. This usually results in late stage detection of the disease, which leads to less chances of patient survival. In the majority of cases, it is diagnosed accidentally, when the patient undergoes checkups for other disorders.
Kidney cancer can be triggered by a number of factors including both lifestyle-related changes and genetic changes. The surgical removal of affected cancerous cells from the kidney provides a complete cure of the disease. A number of drugs are also available, which also help in the treatment of the disease when it is diagnosed at earlier stages.
The report's analysts forecast the global kidney cancer drugs market to grow at a CAGR of 7.36% over the period 2014-2019.

Covered in this Report
The report covers the present scenario and the growth prospects of the global kidney cancer drugs market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various approved therapies and off-label drugs used for the treatment of kidney cancer.
The three regions covered in the report are as follows:
- Americas: US, Canada, Mexico, and Brazil
- EMEA: UK, Germany, Italy, France, and Spain and Middle Eastern and African countries such Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE
- APAC: Japan, China, Australia, Singapore, South Korea, and India.
This market report, Global Kidney Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
- Americas
Key Vendors
- Bayer
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Novartis
- Pfizer
Other Prominent Vendors

- Abbott Laboratories
- Active Biotech
- Amgen
- Argos Therapeutics
- ArQule
- AVEO Pharmaceuticals
- Bionomics
- Bristol-Myers Squibb
- Cerulean Pharma
- Exelixis
- Genentech
- immatics biotechnologies
- Immunicum
- Ono Pharmaceutical
- Onyx Therapeutics
- Oxford BioMedica
- Prometheus Laboratories
- Seattle Genetics
- Taiwan Liposome
- TRACON Pharmaceuticals
- Wilex

Market Driver
- Increase in Patient Population
- For a full, detailed list, view our report
Market Challenge
- High Cost of Drugs
- For a full, detailed list, view our report
Market Trend
- Strategic Alliances
- For a full, detailed list, view our report
Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Market Research International is a leading distributor of PREMIUM market research reports.